Compare Vanguard S&P 500 ETF (VOO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard S&P 500 ETF vs Zoetis Inc — how do they compare? Vanguard S&P 500 ETF trades at $700.9, while Zoetis Inc trades at $73.83 (market cap $30.29B). The key difference: Zoetis Inc pays a 2.89% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VOO | ZTS | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $714.90 | $150.61 |
52-Week Low | $580.93 | $71.91 |
Market Cap | — | $30.29B |
Enterprise Value | — | $37.86B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VOO, the Vanguard S&P 500 ETF, trades at $704.09, down 0.56% on the day, with a neutral technical signal and bullish moving averages. The ETF exhibits consolidation near pivot points, with support at $702 and resistance at $707. Recent news highlights strong ETF inflows and S&P 500 resilience amid geopolitical tensions, while a dividend of $1.96 is scheduled for June 2026.
The outlook for VOO remains positive for long-term investors, supported by historical market gains and low-cost diversification. Risks include elevated valuations, Fed rate uncertainty, and AI concentration in top holdings. Analyst consensus favors holding for steady growth, with institutional interest sustained.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
